Proficio Capital Partners LLC Acquires New Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Proficio Capital Partners LLC bought a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 38,669 shares of the specialty pharmaceutical company’s stock, valued at approximately $4,762,000. Proficio Capital Partners LLC owned 0.06% of Jazz Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Victory Capital Management Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 23.3% during the third quarter. Victory Capital Management Inc. now owns 253,299 shares of the specialty pharmaceutical company’s stock worth $28,220,000 after purchasing an additional 47,807 shares during the last quarter. CIBC Asset Management Inc acquired a new position in Jazz Pharmaceuticals in the third quarter valued at $209,000. Natixis Advisors LLC lifted its position in Jazz Pharmaceuticals by 7.6% during the third quarter. Natixis Advisors LLC now owns 22,834 shares of the specialty pharmaceutical company’s stock worth $2,544,000 after buying an additional 1,603 shares during the period. Swiss National Bank boosted its stake in Jazz Pharmaceuticals by 0.3% in the 3rd quarter. Swiss National Bank now owns 117,000 shares of the specialty pharmaceutical company’s stock worth $13,035,000 after buying an additional 400 shares during the last quarter. Finally, Advisors Asset Management Inc. boosted its stake in Jazz Pharmaceuticals by 3.9% in the 3rd quarter. Advisors Asset Management Inc. now owns 9,624 shares of the specialty pharmaceutical company’s stock worth $1,072,000 after buying an additional 364 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CAO Patricia Carr sold 1,140 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $137.81, for a total transaction of $157,103.40. Following the transaction, the chief accounting officer now directly owns 7,012 shares of the company’s stock, valued at approximately $966,323.72. The trade was a 13.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total transaction of $183,465.00. Following the completion of the transaction, the chief executive officer now owns 439,744 shares of the company’s stock, valued at $53,785,088.64. This trade represents a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 28,736 shares of company stock valued at $4,022,825. Corporate insiders own 4.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. HC Wainwright increased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a report on Monday, March 10th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $130.00 to $170.00 in a research report on Thursday, February 13th. Truist Financial lifted their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Barclays restated an “overweight” rating and set a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Finally, Royal Bank of Canada reduced their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $187.71.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $140.22 on Tuesday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $148.06. The company has a market capitalization of $8.52 billion, a price-to-earnings ratio of 19.75, a PEG ratio of 1.04 and a beta of 0.44. The business has a 50-day moving average of $129.88 and a 200-day moving average of $121.01.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.